杜基酸单胺作为脂肪酸结合蛋白5抑制剂
Chuanzhou Zhu1, Livia Schutz2, Kalani Jayanetti1
1Department of Chemistry, Stony Brook University, Stony Brook, NY, USA.
Bioorganic & medicinal chemistry
|September 14, 2023
概括
新的三酸单胺基 (TAMADs) 是脂肪酸结合蛋白5 (FABP5) 的强效和选择性抑制剂,为开发具有减少副作用的新型止痛药提供了有前途的支架.
科学领域:
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- 脂肪酸结合蛋白 (FABP) 对于脂质运输和调节生物功能至关重要.
- 抑制FABP5显示了镇痛作用,使FABP5抑制剂成为潜在的疼痛治疗药物.
- 现有的FABP5抑制剂 (TAME) 缺乏选择性,特别是对FABP3,需要新的支架.
研究的目的:
- 合成和评估酸单胺 (TAMADs) 作为新型FABP5抑制剂.
- 评估TAMADs对FABP3的选择性及其对FABP5.5的强度.
- 为了检查TAMADs的体内抗受体疗效.
主要方法:
- 在基分子对接中预测结合相互作用.
- 在体外结合测试以确定亲缘关系和选择性.
- 在体内抗受体测试以评估疼痛模型中的疗效.
主要成果:
- 在FABP3.3中,TAMADs表现出异常的选择性.
- 几个TAMAD化合物实现了对FABP5.5的高结合亲和力.
- 在体内,TAMADs表现出与TAMEs相比的抗受效率和持续时间.
结论:
- 在开发强效和选择性的FABP5抑制剂方面,TAMADs是一个有前途的支架.
- 这一新类化合物为止痛药提供了潜力,由于FABP3交叉反应性降低,其安全性有所改善.
- TAMADs为推进FABP5向性疼痛疗法提供了一个可行的替代方案.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
696
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
696
Antidepressant Drugs: MAOIs and Other Agents
270
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
270
Antiasthma Drugs: Leukotriene Modifiers
343
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
343
Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
Factors Affecting Protein-Drug Binding: Protein-Related Factors
191
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
191
Factors Affecting Protein-Drug Binding: Drug-Related Factors
140
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
140


